KSI-501 also met noninferiority to aflibercept, but the topline data did not establish a clear incremental benefit from adding IL-6 inhibition.
Key Takeaways
- Zenkuda and KSI-501 both met the Phase 3 DAYBREAK primary endpoint against aflibercept.
- Zenkuda produced the clearer differentiation: 54% of patients reached a 24-week dosing interval at Year 1.
- KSI-501 did not fail, but its dual VEGF/IL-6 mechanism has not yet demonstrated a clear clinical advantage in a broad wet AMD population.
Data Snapshot
| DAYBREAK result | Zenkuda | KSI-501 |
|---|---|---|
| Mean BCVA gain | +7.2 letters | +6.3 letters |
| Primary endpoint | Noninferiority met, p=0.0007 | Noninferiority met, p=0.0036 |
| Dosing after loading | Individualized Q4W–Q24W | Q8W plus additional treatment as needed |
| Key additional result | 54% reached Q24W dosing | Anatomical endpoint met, p<0.0001 |
| Intraocular inflammation | 0% | 0.4% |
| Cataract adverse events | 0.5% | 0% |
Aflibercept produced a mean best-corrected visual acuity gain of 7.6 letters. The reported p-values demonstrate noninferiority, not superiority.
What Happened?
Kodiak Sciences reported that both Zenkuda and KSI-501 met the primary endpoint of noninferiority to aflibercept in the Phase 3 DAYBREAK trial. Independent coverage identified Zenkuda’s 24-week durability as the clearest positive signal, while noting that its full differentiation will depend on detailed data and the evolving competitive landscape. (Fierce Biotech analysis)
The trial contained parallel Zenkuda and KSI-501 arms, each compared with aflibercept. Zenkuda and KSI-501 were not compared directly with each other.
Following four monthly loading doses, Zenkuda was administered at individualized intervals ranging from four to 24 weeks under a strict treat-to-dry approach. At Year 1, 54% of patients were receiving treatment every 24 weeks while maintaining vision and retinal-fluid control.
KSI-501 was administered every eight weeks after four monthly loading doses, with additional individualized injections available up to monthly dosing. It met both the vision primary endpoint and a key anatomical secondary endpoint.
Kodiak plans to submit a multi-indication Zenkuda biologics license application in the fourth quarter of 2026, supported by five positive Phase 3 studies across wet AMD, diabetic retinopathy and retinal vein occlusion. (Kodiak DAYBREAK results)
How Zenkuda and KSI-501 Work
Wet AMD is driven largely by vascular endothelial growth factor, or VEGF, which promotes abnormal blood-vessel growth and retinal leakage.
Zenkuda, or tarcocimab tedromer, selectively blocks VEGF-A. Its enhanced formulation combines unconjugated protein for rapid VEGF suppression with protein attached to Kodiak’s Antibody Biopolymer Conjugate, or ABC, platform for longer ocular persistence. Zenkuda does not directly bind VEGF-B or placental growth factor, known as PlGF.
KSI-501, or tabirafusp alfa tedromer, is a single bispecific molecule with two functional components. Its VEGF-trap domain binds VEGF-A and PlGF, while its antibody domain neutralizes soluble interleukin-6, or IL-6. The ABC platform is intended to extend the molecule’s residence time inside the eye.
The rationale is to suppress both VEGF-driven vascular leakage and IL-6-mediated inflammation. However, DAYBREAK did not establish a clear incremental clinical benefit from adding IL-6 inhibition in the broad treatment-naïve wet AMD population. This does not prove that IL-6 inhibition has no value; Kodiak is conducting subgroup analyses and continues to evaluate KSI-501 in diabetic macular edema. (Kodiak KSI-501 mechanism)
Zenkuda selectively blocks VEGF-A, while KSI-501 combines VEGF-A/PlGF trapping with IL-6 inhibition. The figure illustrates mechanistic differences, not clinical superiority.
Key Market and Pipeline Competition
| Company | Product | Status | Mechanism | Clinical positioning |
|---|---|---|---|---|
| Regeneron/Bayer | Eylea / Eylea HD | Approved | VEGF-A, VEGF-B and PlGF trap | Established benchmark; Eylea HD offers extended dosing |
| Roche/Genentech | Vabysmo | Approved | VEGF-A and Ang-2 inhibition | Dual-pathway therapy with dosing intervals up to 16 weeks |
| Kodiak Sciences | Zenkuda | Phase 3 completed | VEGF-A antibody plus ABC platform | 54% reached 24-week dosing in DAYBREAK |
| Kodiak Sciences | KSI-501 | Phase 3; ALTO ongoing | VEGF-A/PlGF trap plus IL-6 blockade | Noninferior in wet AMD; differentiation remains under evaluation |
| Merck | Tiespectus, MK-8748 | Phase 2b/3 in wet AMD | VEGF inhibition plus Tie2 activation | Direct pipeline competitor targeting vascular stability |
| Merck | Remigromig, MK-3000 | Positive Phase 2b/3 in DME; Phase 2 in wet AMD/RVO | Wnt-pathway agonist | Novel blood-retinal-barrier repair mechanism; currently an adjacent wet AMD competitor |
| Ocular Therapeutix | AXPAXLI | Phase 3 in wet AMD | Sustained-release axitinib hydrogel | Long-duration pan-VEGFR inhibition |
| Lilly/Adverum | Ixo-vec | Phase 3 in wet AMD | AAV gene therapy encoding aflibercept | Single-administration gene therapy strategy |
Merck’s remigromig met the BRUNELLO Phase 2b/3 primary endpoint in diabetic macular edema, but its wet AMD program remains in Phase 2. Merck’s equivalent-stage wet AMD competitor is Tiespectus, which is being studied in the Phase 2b/3 TORRONTES and MALBEC trials. (Merck ophthalmology pipeline)
AXPAXLI has also reported positive Phase 3 SOL-1 results, illustrating that Zenkuda is entering an increasingly competitive market focused on reducing injection frequency rather than simply matching anti-VEGF efficacy. (Ocular Therapeutix SOL-1 results)
Why It Matters
DAYBREAK produced two statistically positive results, but their strategic value differs.
Zenkuda demonstrated an easily understood benefit: aflibercept-like vision improvement with 24-week dosing in 54% of patients. The remaining questions are whether this durability will be reproduced in routine practice and how Zenkuda will compete with Eylea HD, Vabysmo and late-stage sustained-delivery programs.
KSI-501 met its primary endpoint and should not be described as a failed program. The limitation is that the topline data did not demonstrate obvious added value from IL-6 inhibition in unselected wet AMD patients. Kodiak is therefore looking for responsive subgroups while testing KSI-501 against aflibercept in the Phase 3 ALTO diabetic macular edema study.
BP View
Zenkuda is the stronger commercial outcome from DAYBREAK. Comparable vision improvement and a 24-week interval in more than half of patients provide Kodiak with a credible regulatory and market-positioning story.
KSI-501 achieved a technical Phase 3 success, but mechanism complexity alone does not guarantee clinical differentiation. The next decisive question is whether IL-6 inhibition produces a measurable benefit in selected wet AMD patients or in diabetic macular edema, where inflammatory biology may be more important.
Because these are topline results, full data are still needed to assess the distribution of dosing intervals, rescue treatment, anatomical outcomes and longer-term safety.
Related Post
Want more context on an alternative approach to retinal vascular disease? Read my previous analysis of Merck’s remigromig Phase 2b/3 BRUNELLO results in diabetic macular edema.
About BP
Biopharma Perspective explains the science, clinical data and competitive context behind major biopharma events.
Leave a Reply